(Erenumab)Biosimilar Reference Antibody-GS40239

货号：GS40239

Erenumab is a fully human monoclonal antibody specifically approved for the preventive treatment of migraine in adults. It belongs to a novel class of migraine-specific therapies known as calcitonin gene-related peptide (CGRP) pathway inhibitors. Erenumab functions as a selective and potent CGRP receptor antagonist. Unlike other CGRP inhibitors that target the ligand (the CGRP peptide itself), erenumab uniquely binds directly to the CGRP receptor, thereby preventing the CGRP peptide from activating the receptor complex. This blockade inhibits the downstream neuroinflammatory and vasodilatory signaling believed to be central to migraine initiation and propagation, leading to a reduction in migraine frequency and severity.